While a method of treatment for people with amusia has not been defined, tone differentiation techniques have been used on amusic patients with some success. It was found with this research that children reacted positively to these tone differentiation techniques, while adults found the training annoying. However, further research in this direction would aid in determining if this would be a viable treatment option for people with amusia. Additional research can also serve to indicate which processing component in the brain is essential for normal music development. Also, it would be extremely beneficial to investigate musical learning in relation to amusia since this could provide valuable insights into other forms of learning disabilities such as dysphasia and dyslexia. Notable cases
In fiction
Horatio Hornblower
Grace from Home on the Range
James Fraser from Outlander by Diana Gabaldon
Rodrigo from Mozart in the Jungle

See also
Absolute pitch, the human ability to name a musical note when played or sung (less common than relative pitch)
Auditory agnosia
Cognitive neuroscience of music
Color blindness
Musical aptitude
Music-specific disorders
Relative pitch, the human ability to accurately distinguish pitch intervals (more common than absolute pitch)
Synesthesia
Tonal memory

References
Further reading
Kazez D (1985). "The myth of tone deafness". Music Educators Journal. 71 (8): 46–47. doi:10.2307/3396499. JSTOR 3396499. S2CID 144988256. Kleist, Karl (1962). Sensory aphasia and amusia; the myeloarchitectonic basis. Oxford: Pergamon Press. OCLC 1649635. External links
MedicineNet: Amusia
NIH: Distorted Tunes Test
The Listening Book: Tone-Deaf Choir audio description by W. A. Mathieu
Immunohistochemistry
The tumor cells in Burkitt lymphoma generally strongly express markers of B cell differentiation (CD20, CD22, CD19), as well as CD10 and BCL6. The tumor cells are generally negative for BCL2 and TdT. The high mitotic activity of Burkitt lymphoma is confirmed by nearly 100% of the cells staining positive for Ki67. Treatment
In general, the first line of treatment for Burkitt lymphoma is chemotherapy. A few of these regimens are: the GMALL-B-ALL/NHL2002 protocol, the modified Magrath regimen (R-CODOX-M/IVAC). COPADM, hyper-CVAD, and the Cancer and Leukemia Group B (CALGB) 8811 regimen; these can be associated with rituximab. In older patients, treatment may be dose-adjusted EPOCH with rituximab.The effects of the chemotherapy, as with all cancers, depend on the time of diagnosis. With faster-growing cancers, such as Burkitt, the cancer actually responds faster than with slower-growing cancers. This rapid response to chemotherapy can be hazardous to the patient, as a phenomenon called "tumor lysis syndrome" could occur. Close monitoring of the patient and adequate hydration is essential during the process. Since Burkitt lymphoma has high propensity to spread to the central nervous system (lymphomatous meningitis), intrathecal chemotherapy with methotrexate and/or ARA-C and/or prednisolone is given along with systemic chemotherapy.Chemotherapy

cyclophosphamide
doxorubicin
vincristine
methotrexate
cytarabine
ifosfamide
etoposide
rituximabOther treatments for Burkitt lymphoma include immunotherapy, bone marrow transplants, stem cell transplant, surgery to remove the tumor, and radiotherapy. Prognosis
The prognosis for Burkitt lymphoma is superior in children and increased age is a negative prognostic indicator. The overall cure rate for sporadic Burkitt lymphoma in developed countries is about 90%.